Here is the naive question a smart friend would ask about transcatheter aortic valve replacement: if the whole point is to replace the ring of tissue that stopped working, why would you build a valve that deliberately avoids sitting in that ring? A patent application published on July 16, 2026 takes exactly that position. US20260199086A1, titled PROSTHETIC HEART VALVES AND METHODS FOR SUPRA-ANNULAR IMPLANTATION, is assigned to Edwards Lifesciences Corporation and names Nikolai Gurovich and Tamir S. Levi as inventors. It is classified under A61F 2/2418, A61F 2/2436 and A61F 2220/0008 — the heart-valve prosthesis art. And notably, its independent claims are directed to methods, not to a device.

The background worth holding in mind is how these valves get placed. A transcatheter valve is a metal frame carrying leaflets, crimped down to catheter diameter, threaded up through the vasculature, and expanded once it reaches the aortic root. In plain terms, the frame is both the scaffold and the anchor: expanding it wedges it against surrounding tissue, and where it wedges determines what it presses on. The aortic annulus — the fibrous ring at the base of the native valve — is the conventional anchoring zone. Just downstream sits the sinotubular junction, or STJ, the shoulder where the bulged sinus region narrows back into the ascending aorta. The distance between those two landmarks defines a short vertical corridor, and this application is about landing inside it.

Claim 1 recites four steps and then a constraint. Insert the distal end portion of a delivery apparatus carrying the valve in a radially compressed state into the patient's vasculature; advance until the compressed valve is within the aortic root; align it relative to one or more anatomical features of the root; and radially expand it. The distinguishing limitation is the closing wherein clause: once expanded, the inflow end of the frame is above the annulus and the outflow end is below the STJ. In claim-scope terms, that is the whole invention in one line — not a new leaflet material, not a new delivery mechanism, but a rule about where the expanded frame comes to rest.

Which raises the obvious engineering objection: you can only park a frame between two landmarks if the frame is shorter than the gap. Claim 8 states that precondition directly, reciting that the height of the frame is less than the distance between the annulus and the STJ. Claim 9 puts numbers on it, reciting a frame height in a range of 15.5 mm to 22.5 mm. That band is the tell. It says the design space here is not arbitrary — it is bounded on the low end by whatever hydraulic and structural performance a frame that short can still deliver, and on the high end by the anatomy of the corridor itself.

The measurement comes before the valve

Claim 14 is a second independent method, and it is the one that reads most like a procedure manual. Rather than treating frame height as a happy coincidence, it makes the measurement the first affirmative step, then makes valve selection the second:

determining a distance between an annulus and an STJ of an aortic root of the patient; selecting a prosthetic heart valve that has a height in a radially expanded state that is less than the distance between the annulus and the STJ— US20260199086A1, US20260199086A1

The rest of claim 14 tracks claim 1 — insert, advance until the compressed valve is between the native leaflets, expand — and closes with the same positional wherein: inflow end above the annulus, outflow end below the STJ. Claim 16 repeats the 15.5 mm to 22.5 mm band as a dependent limitation. The structural difference between the two independent claims is where the burden sits. Claim 1 describes an outcome achieved during the procedure. Claim 14 describes a workflow in which the patient's own corridor dimension is a gating input to device choice, which in practice means imaging and sizing work done before anyone is on the table. Claim 17 is a third independent method, stripped down to the expansion step alone and the resulting position of the frame.

Anchoring is the part of the story the abstract foregrounds. As background description, the abstract characterizes the disclosure as covering valves, delivery apparatus and methods for preventing or limiting migration of an implanted prosthetic valve, and notes that the valve can additionally include one or more anti-migration features. The claims put specific hardware behind that description. Claim 10 adds a step of deploying one or more anti-migration features; claim 11 narrows it to deploying frame anchors over a native leaflet free edge — using the patient's own leaflets as a hooking surface. Claim 12 recites engaging an annular flange of an outer skirt with native tissue above the annulus. Claim 13 adds an ingrowth-resistant annular extension that extends into the annulus when the valve is expanded. Read together, claims 10 through 13 are the answer to the objection that a frame not seated in the annulus has less to hold onto: the fixation moves to the leaflets, to a skirt flange, and to a tissue extension, and it is distributed rather than concentrated in one radial wedge.

Two directional vocabularies in one document

Anyone reading the claim set closely will hit a wrinkle worth flagging, because it changes how the document should be quoted. Claim 17, like claim 1 and the abstract, uses anatomical terms: the inflow end of the frame is above an annulus of an aortic valve and the outflow end is below a sinotubular junction. Claims 18 and 20 use flow-direction terms instead, reciting that the entirety of the frame, and then the entirety of the valve, is within the aortic root upstream of the annulus of the aortic valve and downstream of the STJ. Since blood in the aortic root travels from annulus toward STJ, those two vocabularies do not map onto each other cleanly as published. Resolving which reading governs is a matter for prosecution, not for a reader, and the responsible move is to attribute each phrasing to the claim it came from and not merge them.

A related staging point applies to claims 2 and 3. Both recite positioning that is the reverse of claim 1's closing clause — inflow end below the annulus, outflow end above the STJ — but they attach to the aligning step, while the valve is still radially compressed, during alignment. Claim 1's positional requirement describes the deployed, radially expanded state. The two describe different moments in the same procedure, and a compressed frame that overshoots the corridor at both ends before shortening into it on expansion is a coherent sequence rather than a contradiction.

Placed against the assignee's recent output, the application sits in a cluster concerned with how a valve holds still and how it seals. US20260137510A1, on prosthetic valves and delivery assemblies with positioning arms, is the nearest sibling on axial positioning; US20260191639A1, on a sealing member for a prosthetic heart valve, pairs naturally with the outer-skirt and flange limitations here. Nearby publications cover frame and leaflet construction (US20260183105A1, US20260183104A1), leaflets with polymeric tissue-adherent surfaces (US20260174553A1), a skirt with a thromboresistant portion (US20260137514A1), and delivery-side work on expandable sheaths (US20260151596A1, US20260137517A1). All of these, including the hero, are published applications rather than granted patents — the claim language described above is what was filed and published, not what has been allowed.